Pharmaceutical company AstraZeneca PLC (NYSE: AZN) said Friday it has won U.S. approval for use of its schizophrenia drug Seroquel XR as an add-on treatment for major depressive disorder, according to Associated Press.
However, the London-based company said that the U.S. Food and Drug Administration has asked for more information before allowing the drug's use as a single agent to treat major depressive disorder, or MDD.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Seroquel XR is an extended-release version of AstraZeneca's schizophrenia medication Seroquel, a major seller for the company. It is already approved for bipolar disorder and schizophrenia.
AstraZeneca said it is evaluating the FDA's request.
The statement comes a day after AstraZeneca announced a deal to develop a depression drug with Targacept Inc. AstraZeneca is paying Targacept $200 million upfront upon effectiveness of TC-5214, Targacept's late-stage investigational treatment for MDD.
AstraZeneca shares were up 1.1 percent at 2,802 pence ($46.64) in midday trade in London.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
